Navigation Links
Kidney-disease drug with Dartmouth origins licensed in Asia
Date:1/14/2010

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

In a deal worth $272 million plus royalties, the firm Kyowa Hakko Kirin bought exclusive rights to the compound bardoxolone methylor CDDO-methyl ester (CDDO-Me), in the scientific literaturefrom Texas-based Reata Pharmaceuticals on Thursday, January 7.

The drug belongs to a family of anti-inflammatory compounds called triterpenoids, which chemist Tadashi Honda, Ph.D., began synthesizing at the Dartmouth laboratory of Gordon Gribble, Ph.D., in 1995. Since then, Dartmouth Medical School pharmacologist Michael B. Sporn, M.D., and his lab team have been testing them for bioactivity.

Sporn and members of his lab, including co-investigator Karen Liby, Ph.D., found in animal trials that synthetic triterpenoids simultaneously inhibit many kinds of tumor cells, suppress inflammation, and protect healthy, non-cancerous cells. While focusing on cancer prevention and treatment, the researchers found that the anti-inflammatory, anti-oxidant and cyto-protective properties of triterpenoids also can apply to a wide range of inflammation-related diseases. These conditions include diseases of the kidney, the heart, the respiratory system, and the central-nervous system.

Triterpenoids "are not anti-oxidants themselves," explains Sporn, DMS's Oscar M. Cohn '34 Professor of Pharmacology and of Medicine. "They turn on the body's own anti-oxidant defenses, which is most important."

Following up on the Sporn lab's cancer research, collaborators at Cornell reported that in tests on rodents, one of the triterpenoids appears to help in preventing such neurodegenerative diseases as Parkinson's, Alzheimer's and Huntington's.

After securing patent protection for the CDDO-Me compounds, Dartmouth College's Technology Transfer Office (TTO) identified Reata as a private-sector collaborator for further development. Under a licensing agreement with Dartmouth, Reata has been conducting human trials with the compounds.

In announcing the deal with Kyowa, Reata reported that "in two Phase 2 trials, bardoxolone significantly improved renal function in Type-2 diabetic patients with advanced CKD. ... Significant improvements were also seen in other markers of renal function, [control of blood-sugar levels], and cardiovascular disease."

The agreement gives Kyowa exclusive rights to develop and sell bardoxolone for CKD and related conditions in Japan, China, Taiwan, Korea and southeast Asia. Reata retains the rights to develop and sell the drug in the United States, Europe, Latin America, and Asian markets beyond Kyowa's territory.

According to Alla Kan, TTO director, the Reata/Kyowa agreement "provides a wonderful opportunity for Dartmouth to bring the fruits of our research to patients. This is a most exciting development and a vivid illustration of academic research transfer to industry for the benefit of humanity."

Sporn, considered "the father of chemoprevention" for his pioneering use of medications to fend off cancer and other diseases, hails the agreement as the culmination of a new drug going " 'all the way' at Dartmouth, from conception, to synthesis, to preclinical development, and then to final licensing to a pharmaceutical company for clinical development."

Sporn also praises the work of his collaborators, particularly Liby and her experiments with mice.

"This woman has a unique talent for doing research," Sporn says.


'/>"/>

Contact: David Corriveau
dms.communications@dartmouth.edu
603-650-0771
Dartmouth College
Source:Eurekalert

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Rural patients colon and lung cancers diagnosed earlier, Dartmouth research says
3. Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas
4. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
5. Dartmouth research reveals passive learning imprints on the brain just like active learning
6. Dartmouth researchers say too many children see extreme violence in movies
7. Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care
8. Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project
9. Dr. Jim Yong Kim Appointed 17th President of Dartmouth College
10. Dartmouth-Hitchcock Medical Center Selects MedAptus for Charge Capture Deployment
11. Dartmouth gets $3 million from the National Science Foundation for IT research in health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology: